Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study - PubMed
6 hours ago
- #Type 2 Diabetes
- #Cardiovascular Risk
- #DPP4 Inhibitors
- The study compares cardiovascular risks of four DPP4 inhibitors: alogliptin, linagliptin, saxagliptin, and sitagliptin in adults with type 2 diabetes and moderate cardiovascular risk.
- Using claims data from 2014-2021 on 184,660 patients, it found MACE rates at 1 year were 2.2% for sitagliptin and linagliptin, 2% for saxagliptin, and 1.7% for alogliptin.
- Saxagliptin showed a modestly decreased risk of MACE compared to sitagliptin (HR 0.94) and linagliptin (HR 0.94), but no significant differences in heart failure hospitalization or hypoglycemia risks were observed.
- Overall, cardiovascular and hypoglycemia risks were comparable across all DPP4 inhibitors, suggesting medication choice can be based on availability.